Faruqi & Faruqi Investigates Potential Claims Against Inovio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy INO?
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against Inovio Pharmaceuticals, specifically targeting investors who purchased securities between October 10, 2023, and December 26, 2025, aiming to provide legal support for affected investors.
- Overview of Allegations: The complaint alleges that Inovio and its executives violated federal securities laws, particularly citing deficiencies in the manufacturing of the CELLECTRA device, which hindered the timely submission of the INO-3107 Biologics License Application (BLA) and negatively impacted the company's market outlook.
- FDA Response and Stock Price Impact: On December 29, 2025, the FDA accepted Inovio's BLA but noted that the company failed to provide adequate information for accelerated approval, resulting in a 24.45% drop in Inovio's stock price to $1.73 per share, reflecting market concerns about the company's future prospects.
- Investor Action Call: Faruq & Faruqi encourages anyone with information, including former employees and shareholders, to contact the firm, emphasizing investors' rights and potential recovery opportunities in the class action lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.660
Low
3.00
Averages
7.33
High
13.00
Current: 1.660
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select law firms, with Rosen Law Firm recommending choosing qualified counsel with a successful track record in securities class actions to ensure optimal representation in litigation.
See More
Inovio Pharmaceuticals Investors Class Action Reminder
- Class Action Notice: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025.
- Financial Impact: On August 8, 2024, Inovio's Q2 2024 financial results revealed a delay in submitting the Biologics License Application (BLA) to mid-2025 due to manufacturing issues, causing a 3.1% drop in stock price to $8.44 per share the following day, resulting in investor losses.
- FDA Review Update: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA on a standard review timeline instead of the anticipated accelerated review, leading to a 24.45% decline in stock price to $1.73 per share, further exacerbating investor losses.
- Lawsuit Allegations: The class action alleges that Inovio failed to disclose manufacturing deficiencies in its CELLECTRA device and overstated the regulatory and commercial prospects of INO-3107, misleading investors and exposing them to significant risks.
See More
Inovio Pharmaceuticals Q4 Results Exceed Expectations
- Earnings Beat: Inovio Pharmaceuticals reported a diluted loss of $0.26 per share for Q4, surpassing the analyst consensus of $0.38 and improving from a $0.65 loss a year prior, indicating positive financial momentum for the company.
- Reduced Annual Loss: The company recorded a net loss of $84.9 million for the full year 2025, down from $107.3 million in 2024, while total operating expenses decreased from $112.6 million to $86.9 million, reflecting effective cost management strategies.
- FDA Application Progress: The FDA has accepted Inovio's biologics license application for INO-3107, aimed at treating recurrent respiratory papillomatosis, with a target action date of October 30, enhancing investor confidence in the company's future market potential.
- Cash Runway Extended: Inovio ended 2025 with $58.5 million in cash and short-term investments, with current resources expected to fund operations into Q4 2026, demonstrating robust financial planning and resource management.
See More
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, urging investors who purchased shares between October 10, 2023, and December 26, 2025, to contact them before the April 7, 2026, deadline to seek lead plaintiff status.
- Regulatory Compliance Issues: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in the CELLECTRA device, which diminished the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024.
- Significant Stock Price Drop: Following the FDA's acceptance of Inovio's INO-3107 BLA, the company's stock price plummeted by 24.45% to close at $1.73 per share on December 29, 2025, indicating market concerns regarding its regulatory and commercial prospects.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information about Inovio's conduct, including whistleblowers and former employees, to come forward to support the ongoing class action lawsuit, ensuring that investors' rights are safeguarded.
See More
Inovio Pharmaceuticals Q4 2025 Earnings Call Insights
- BLA Review Progress: Inovio's first Biologics License Application (BLA) for INO-3107 is under FDA review with a target date of October 30, 2026, indicating the company's potential in treating recurrent respiratory papillomatosis, which could significantly enhance its market competitiveness if approved.
- Financial Condition Improvement: As of Q4 2025, Inovio reported $58.5 million in cash and short-term investments, down from $94.1 million at the end of 2024, although operating expenses decreased from $20.5 million to $17.5 million, reflecting the company's efforts in cost control.
- Strategic Focus Adjustment: The company has extended its cash runway into Q4 2026 by reducing headcount by approximately 15% and rescoping projects, ensuring operational stability during the FDA review period.
- Collaboration and R&D: Inovio's collaboration with Akeso for a Phase II adaptive platform trial evaluating INO-5412 in combination with a novel bispecific antibody indicates the company's proactive approach in advancing next-generation DNA medicines, aiming to expand its product line and market opportunities.
See More
Inovio Pharmaceuticals Reports FY GAAP EPS Beat
- Earnings Report Beat: Inovio Pharmaceuticals reported a FY GAAP EPS of -$1.81, surpassing market expectations by $0.42, indicating improvements in financial management despite still operating at a loss.
- Conference Presentation: At the 2026 Citizens Life Sciences Conference, Inovio showcased its latest research advancements, capturing investor interest and potentially paving the way for future financing and collaboration opportunities.
- FDA Review Impact: Inovio's INO-3107 project is under FDA review, presenting both risks and opportunities; successful approval could significantly enhance the company's market position in the biopharmaceutical sector.
- Asset Evaluation Challenges: Inovio's stock dropped after its respiratory papillomatosis asset was denied accelerated review, highlighting challenges in product development and market promotion that may affect future investor confidence.
See More
Inovio Pharmaceuticals Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong reputation in the field.
- Investor Guidance: Investors are advised to carefully select law firms, with Rosen Law Firm recommending choosing qualified counsel with a successful track record in securities class actions to ensure optimal representation in litigation.
See More
Inovio Pharmaceuticals Investors Class Action Reminder
- Class Action Notice: Glancy Prongay Wolke & Rotter LLP reminds investors that April 7, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025.
- Financial Impact: On August 8, 2024, Inovio's Q2 2024 financial results revealed a delay in submitting the Biologics License Application (BLA) to mid-2025 due to manufacturing issues, causing a 3.1% drop in stock price to $8.44 per share the following day, resulting in investor losses.
- FDA Review Update: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA on a standard review timeline instead of the anticipated accelerated review, leading to a 24.45% decline in stock price to $1.73 per share, further exacerbating investor losses.
- Lawsuit Allegations: The class action alleges that Inovio failed to disclose manufacturing deficiencies in its CELLECTRA device and overstated the regulatory and commercial prospects of INO-3107, misleading investors and exposing them to significant risks.
See More
Inovio Pharmaceuticals Q4 Results Exceed Expectations
- Earnings Beat: Inovio Pharmaceuticals reported a diluted loss of $0.26 per share for Q4, surpassing the analyst consensus of $0.38 and improving from a $0.65 loss a year prior, indicating positive financial momentum for the company.
- Reduced Annual Loss: The company recorded a net loss of $84.9 million for the full year 2025, down from $107.3 million in 2024, while total operating expenses decreased from $112.6 million to $86.9 million, reflecting effective cost management strategies.
- FDA Application Progress: The FDA has accepted Inovio's biologics license application for INO-3107, aimed at treating recurrent respiratory papillomatosis, with a target action date of October 30, enhancing investor confidence in the company's future market potential.
- Cash Runway Extended: Inovio ended 2025 with $58.5 million in cash and short-term investments, with current resources expected to fund operations into Q4 2026, demonstrating robust financial planning and resource management.
See More
Faruqi & Faruqi Investigates Inovio Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential securities fraud claims against Inovio Pharmaceuticals, urging investors who purchased shares between October 10, 2023, and December 26, 2025, to contact them before the April 7, 2026, deadline to seek lead plaintiff status.
- Regulatory Compliance Issues: The complaint alleges that Inovio and its executives violated federal securities laws by failing to disclose manufacturing deficiencies in the CELLECTRA device, which diminished the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024.
- Significant Stock Price Drop: Following the FDA's acceptance of Inovio's INO-3107 BLA, the company's stock price plummeted by 24.45% to close at $1.73 per share on December 29, 2025, indicating market concerns regarding its regulatory and commercial prospects.
- Investor Rights Protection: Faruq & Faruq LLP encourages anyone with information about Inovio's conduct, including whistleblowers and former employees, to come forward to support the ongoing class action lawsuit, ensuring that investors' rights are safeguarded.
See More
Inovio Pharmaceuticals Q4 2025 Earnings Call Insights
- BLA Review Progress: Inovio's first Biologics License Application (BLA) for INO-3107 is under FDA review with a target date of October 30, 2026, indicating the company's potential in treating recurrent respiratory papillomatosis, which could significantly enhance its market competitiveness if approved.
- Financial Condition Improvement: As of Q4 2025, Inovio reported $58.5 million in cash and short-term investments, down from $94.1 million at the end of 2024, although operating expenses decreased from $20.5 million to $17.5 million, reflecting the company's efforts in cost control.
- Strategic Focus Adjustment: The company has extended its cash runway into Q4 2026 by reducing headcount by approximately 15% and rescoping projects, ensuring operational stability during the FDA review period.
- Collaboration and R&D: Inovio's collaboration with Akeso for a Phase II adaptive platform trial evaluating INO-5412 in combination with a novel bispecific antibody indicates the company's proactive approach in advancing next-generation DNA medicines, aiming to expand its product line and market opportunities.
See More
Inovio Pharmaceuticals Reports FY GAAP EPS Beat
- Earnings Report Beat: Inovio Pharmaceuticals reported a FY GAAP EPS of -$1.81, surpassing market expectations by $0.42, indicating improvements in financial management despite still operating at a loss.
- Conference Presentation: At the 2026 Citizens Life Sciences Conference, Inovio showcased its latest research advancements, capturing investor interest and potentially paving the way for future financing and collaboration opportunities.
- FDA Review Impact: Inovio's INO-3107 project is under FDA review, presenting both risks and opportunities; successful approval could significantly enhance the company's market position in the biopharmaceutical sector.
- Asset Evaluation Challenges: Inovio's stock dropped after its respiratory papillomatosis asset was denied accelerated review, highlighting challenges in product development and market promotion that may affect future investor confidence.
See More
